Effective February 2, 2026, the US Food and Drug Administration (FDA) began implementing the new Quality Management System Regulation (QMSR), which represents a fundamental shift in how medical device manufacturers are regulated and inspected. This step comes to incorporate the requirements of the international standard ISO 13485:2016 into federal regulations, aiming to align US requirements with global standards followed by other regulatory bodies.
Radical Changes in Inspection Processes
With the regulation entering into force, the FDA has officially discontinued the use of the previous Quality System Inspection Technique (QSIT) and replaced it with an updated compliance program under code 7382.850. This change means that inspectors will now rely on ISO 13485 standards to evaluate companies' quality management systems, reducing the regulatory gap between the US market and international markets.
What Changes Practically for Manufacturers?
The most prominent changes that companies must pay attention to include:
- Elimination of Previous Exemptions: Records related to internal audits, supplier audits, and management review reports are no longer protected from inspection as they were under the old regulation (820.180(c)). These documents are now available to FDA inspectors upon request.
- Compatibility with Historical Records: The FDA confirmed that the new requirements are substantially similar to the previous ones, but it recommends that companies conduct a gap analysis to ensure that records created before February 2026 meet the updated standards.
- Independence of Inspection: The agency clarified that its inspections remain independent of the Medical Device Single Audit Program (MDSAP), and that obtaining a certificate of conformity with ISO 13485 from a third party does not exempt a company from federal inspection.
Why Does This Change Matter?
This move aims to enhance the efficiency of regulatory oversight and facilitate the faster entry of safe, high-quality medical devices into the market. By adopting an international standard, the FDA seeks to reduce administrative burdens on companies operating in multiple markets, while maintaining a high level of quality assurance and patient safety. The agency also confirmed that it will continue to update its technical systems and train its staff to ensure the effective implementation of the new regulation, while remaining committed to reviewing any future updates to the ISO standard to assess the need for future amendments to US regulations.